Vaccine is tested against mosquito-borne diseases

A new vaccine can protect against a range of mosquito-borne diseases such as Zika, malaria, West Nile virus and dengue being tested.

Researchers from the US National Institutes of Health (NIH) are testing a new vaccine designed to target mosquito saliva to protect against mosquito-borne diseases .

The National Institute of Allergy and Infectious Diseases (NIAID) under NIH has conducted a clinical trial of phase 1 of a new vaccine that can protect against a variety of mosquito-borne diseases such as Zika, malaria, West Nile virus and fever. hemorrhage.

The vaccine is designed to create an immune response to mosquito saliva instead of a virus or parasite.

The AGS-v Vaccine is a product of the London-based SEEK pharmaceutical company, designed to create an immune response to mosquito saliva instead of a virus or parasite. AGS-v is made up of 4 synthetic proteins from the salivary glands of mosquitoes and is designed to create antibodies in vaccinated people to cause a changing allergic reaction to prevent infection.

This trial included 60 healthy people aged 18 to 50 and divided into 3 groups. The first group will receive 2 doses of AGS-v spaced 21 days apart. Group 2 received 2 doses of AGS-v in combination with excipients including oil and water 21 days apart. Group 3 with 2 placebo injections included sterile water spaced 21 days apart. Phase 1 clinical trial is expected to be completed in the summer of 2018.

NIAID director Dr. Anthony S. Fauci said: "Mosquitoes can cause more diseases and deaths in humans than other species. A vaccine that protects against mosquito-borne diseases is a point of view. new, and if proven successful, it will bring great public health benefits ".